Journal
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
Volume 8, Issue 2, Pages 132-140Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11899-013-0153-6
Keywords
Acute myeloid leukemia; Allogeneic hematopoietic cell transplant; Relapse; Strategies
Categories
Funding
- NCI NIH HHS [P01 CA044991] Funding Source: Medline
- NHLBI NIH HHS [T32 HL007093] Funding Source: Medline
Ask authors/readers for more resources
The incidence of acute myeloid leukemia (AML) is expected to increase in conjunction with our ageing population. Although it is proving to be a heterogeneous disease process, the only treatment with proven survival benefit for poor risk AML remains allogeneic hematopoietic cell transplant. Although this is presumed to be a curative strategy, many patients relapse after transplant, prompting us to examine various ways that we can improve outcomes. These efforts involve every step of AML diagnostics and therapy, including the intricate processes of conditioning, graft manipulation and immunomodulation. The hope is that improvement in these steps will ultimately improve survival and decrease relapse rates for AML patients after transplant.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available